Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Head and Neck Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 32 articles:
HTML format
Text format



Single Articles


    May 2019
  1. THORWARTH D, Welz S, Monnich D, Pfannenberg C, et al
    Prospective evaluation of a tumor control probability model based on dynamic (18)F-FMISO PET for head-and-neck cancer radiotherapy.
    J Nucl Med. 2019 May 10. pii: jnumed.119.227744. doi: 10.2967/jnumed.119.227744.
    PubMed     Text format     Abstract available


    March 2019
  2. VALKEMA MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, et al
    Accuracy of (18)F-FDG PET/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.
    J Nucl Med. 2019 Mar 15. pii: jnumed.118.224196. doi: 10.2967/jnumed.118.224196.
    PubMed     Text format     Abstract available


    February 2019
  3. VAN KEULEN S, Nishio N, Fakurnejad S, Birkeland A, et al
    The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.
    J Nucl Med. 2019 Feb 7. pii: jnumed.118.222810. doi: 10.2967/jnumed.118.222810.
    PubMed     Text format     Abstract available


    November 2018
  4. SELVAKUMAR T, Nies M, Klein Hesselink MS, Brouwers AH, et al
    Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma.
    J Nucl Med. 2018 Nov 30. pii: jnumed.118.212449. doi: 10.2967/jnumed.118.212449.
    PubMed     Text format     Abstract available


    October 2018
  5. ROHDE M, Nielsen AL, Pareek M, Johansen J, et al
    PET/CT versus standard imaging for prediction of survival in patients with recurrent head and neck squamous cell carcinoma.
    J Nucl Med. 2018 Oct 12. pii: jnumed.118.217976. doi: 10.2967/jnumed.118.217976.
    PubMed     Text format     Abstract available


  6. LEE H, Lazor JW, Assadsangabi R, Shah J, et al
    An imager's guide to perineural tumor spread in head and neck cancers: radiological footprints on (18)F-FDG PET with CT and MRI correlates.
    J Nucl Med. 2018 Oct 5. pii: jnumed.118.214312. doi: 10.2967/jnumed.118.214312.
    PubMed     Text format     Abstract available


    April 2018
  7. TULCHINSKY M, Binse I, Campenni A, Dizdarevic S, et al
    Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.211359. doi: 10.2967/jnumed.118.211359.
    PubMed     Text format    


    December 2017
  8. TESSELAAR MH, Crezee T, Schuurmans I, Gerrits D, et al
    Digitalis-like compounds restore hNIS expression and iodide uptake capacity in anaplastic thyroid cancer.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.200675. doi: 10.2967/jnumed.117.200675.
    PubMed     Text format     Abstract available


    October 2017
  9. WERNER RA, Schmid JS, Higuchi T, Javadi MS, et al
    Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib.
    J Nucl Med. 2017 Oct 12. pii: jnumed.117.199778. doi: 10.2967/jnumed.117.199778.
    PubMed     Text format     Abstract available


  10. PATTISON DA, Bozin M, Gorelik A, Hofman MS, et al
    18F-fluorodeoxyglycose-avid thyroid incidentalomas: the importance of contextual interpretation.
    J Nucl Med. 2017 Oct 12. pii: jnumed.117.198085. doi: 10.2967/jnumed.117.198085.
    PubMed     Text format     Abstract available


    September 2017
  11. ROHDE M, Nielsen AL, Pareek M, Johansen J, et al
    A PET/CT-based strategy is a stronger predictor of survival than a standard imaging strategy in patients with head and neck squamous cell carcinoma.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.197350. doi: 10.2967/jnumed.117.197350.
    PubMed     Text format     Abstract available


    June 2017
  12. O'DONOGHUE JA, Lewis JS, Pandit-Taskar N, Fleming SE, et al
    Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.194555. doi: 10.2967/jnumed.117.194555.
    PubMed     Text format     Abstract available


  13. NA KJ, Choi H
    Tumor metabolic features identified by FDG PET correlates with gene networks of immune cell microenvironment in head and neck cancer.
    J Nucl Med. 2017 Jun 6. pii: jnumed.117.194217. doi: 10.2967/jnumed.117.194217.
    PubMed     Text format     Abstract available


  14. ROHDE M, Nielsen AL, Johansen J, Sorensen JA, et al
    Head-to-head comparison of chest x-ray/head and neck MRI, chest CT/head and neck MRI, and 18F-FDG-PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal Cancer.
    J Nucl Med. 2017 Jun 1. pii: jnumed.117.189704. doi: 10.2967/jnumed.117.189704.
    PubMed     Text format     Abstract available


    May 2017
  15. XI M, Liao Z, Hofstetter WL, Komaki R, et al
    FDG-PET Response After Induction Chemotherapy Can Predict Who Will Benefit From Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.
    J Nucl Med. 2017 May 18. pii: jnumed.117.192591. doi: 10.2967/jnumed.117.192591.
    PubMed     Text format     Abstract available


    April 2017
  16. DEANDREIS D, Schlumberger M, Tuttle RM
    Reply: Fixed 100 mCi I-131 Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.193185. doi: 10.2967/jnumed.117.193185.
    PubMed     Text format    


  17. NICHOLS KJ, Robeson W, Yoshida-Hay M, Zanzonico PB, et al
    Alternative Means of Estimating 131I Maximum Permissible Activity to Treat Thyroid Cancer.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.192278. doi: 10.2967/jnumed.117.192278.
    PubMed     Text format     Abstract available


  18. O' DOHERTY J, Jauregui-Osoro M, Brothwood T, Szyszko T, et al
    18F-tetrafluoroborate (18F-TFB), a PET probe for imaging sodium-iodide symporter expression: Whole-body biodistribution, safety and radiation dosimetry in thyroid cancer patients.
    J Nucl Med. 2017 Apr 6. pii: jnumed.117.192252. doi: 10.2967/jnumed.117.192252.
    PubMed     Text format     Abstract available


  19. JENTZEN W, Nahum AE, Bockisch A, Binse I, et al
    Fixed 100 mCi I-131 Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History.
    J Nucl Med. 2017 Apr 6. pii: jnumed.117.192872. doi: 10.2967/jnumed.117.192872.
    PubMed     Text format    


    February 2017
  20. VAN NOSTRAND D
    Prescribed activities of I-131 therapies in differentiated thyroid cancer: Invited Commentary.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.188862. doi: 10.2967/jnumed.116.188862.
    PubMed     Text format    


  21. FLUX GD, Verburg FA, Chiesa C, Bardies M, et al
    Comparison of empiric versus whole body/blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer.
    J Nucl Med. 2017 Feb 9. pii: jnumed.116.186643. doi: 10.2967/jnumed.116.186643.
    PubMed     Text format    


    January 2017
  22. PLYKU D, Hobbs RF, Huang K, Atkins F, et al
    Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.179366. doi: 10.2967/jnumed.116.179366.
    PubMed     Text format     Abstract available


    October 2016
  23. DEANDREIS D, Rubino C, Tala H, Leboulleux S, et al
    Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.179606.
    PubMed     Text format     Abstract available


    August 2016
  24. YANG X, Li J, Li X, Liang Z, et al
    TERT promoter mutation predicts radioiodine refractory in distant metastatic differentiated thyroid cancer.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.180240.
    PubMed     Text format     Abstract available


    May 2016
  25. JENTZEN W, Verschure F, van Zon A, van de Kolk R, et al
    Response Assessment of Bone Metastases from Differentiated Thyroid Cancer Patients in the Initial Radioiodine Treatment Using Iodine-124 PET Imaging.
    J Nucl Med. 2016 May 19. pii: jnumed.115.170571.
    PubMed     Text format     Abstract available


  26. LIN CY, Lin CL, Kao CH
    Reply: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 19. pii: jnumed.116.178152.
    PubMed     Text format    


  27. RUHLMANN M, Jentzen W, Ruhlmann V, Pettinato C, et al
    High Level of Agreement between Pretherapeutic 124I PET and Intratherapeutic 131I Images in Detecting Iodine-positive Thyroid Cancer Metastases.
    J Nucl Med. 2016 May 5. pii: jnumed.115.169649.
    PubMed     Text format     Abstract available


    March 2016
  28. PATTISON DA, Solomon B, Hicks RJ
    A New Theranostic Paradigm for Advanced Thyroid Cancer.
    J Nucl Med. 2016 Mar 31. pii: jnumed.116.173534.
    PubMed     Text format    


    February 2016
  29. WIERTS R, Brans B, Havekes B, Kemerink G, et al
    Dose-response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    J Nucl Med. 2016 Feb 25. pii: jnumed.115.168799.
    PubMed     Text format     Abstract available


  30. LIN CM, Yeh PT, Doyle P, Tsan YT, et al
    Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery-a cohort study from Taiwan.
    J Nucl Med. 2016 Feb 2. pii: jnumed.115.167197.
    PubMed     Text format     Abstract available


    December 2015
  31. LIN CY, Lin CL, Huang WS, Kao CH, et al
    Risk of Breast Cancer in Patients With Thyroid Cancer Receiving or Not Receiving I-131 Treatment: A Nationwide Population-based Cohort Study.
    J Nucl Med. 2015 Dec 30. pii: jnumed.115.164830.
    PubMed     Text format     Abstract available


    November 2015
  32. KIST JW, de Keizer B, van der Vlies M, Brouwers AH, et al
    124I PET/CT to predict the outcome of blind 131I treatment in patients with biochemical recurrence of differentiated thyroid cancer; results of a multicenter diagnostic cohort study (THYROPET).
    J Nucl Med. 2015 Nov 25. pii: jnumed.115.168138.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: